Summary Lung cancer is strictly associated with tobacco smoking. Tumours developed in non-smoking subjects account for less than 10% of all lung cancers and show peculiar histopathlIogical features, being prevalentty adenocarcinomas. A number of genetic data suggest that their biological behaviour may be different from that of lung tumours caused by smoking, however the number of cases investigated to date is too low to draw definitive conclusions. We have examined the status of p53 and K-ras genes and the presence of loss of heterozygosity (LOH) at the FHIT locus in a series of 35 lung adenocarcinomas that developed in subjects who had never smoked. Results were compared with those obtained in a series of 35 lung adenocarcinromas from heavy-smoking subjects. In the group of non-smoking subjects p53 mutations and LOH at the FHIT locus were present in seven (20%) cases, and the two alterations were constantly associated (P < 0.0001), whereas they were not related in the series of carcinomas caused by smoking. In tumours developed in heavy-smoking subjects, the frequency of LOH at the FHIT locus was significantly higher (P = 0.006) than in tumours from non-smoking subjects. The frequency of p53 mutations in adenocarcinomas caused by smoking was not different from that seen in non-smoking subjects. However, in the group of smoking subjects we observed mostly G:C -* T:A transversions, whereas frameshift mutations and G:C -* A:T transitions were more frequently found in tumours from non-smoking subjects. No point mutations of the K-ras gene at codon 12 were seen in subjects who had never smoked, whereas they were present (mostly G:C -* T:A transversions) in 34% of tumours caused by smoking (P = 0.002). Our data suggest that lung adenocarcinomas developed in subjects who had never smoked represent a distinct biological entity invoMng a co-alteration of the p53 gene and the FHIT locus in 20% of cases.
Lung cancer, the predominant cause of cancer-related death throughout the world, is strictly related to tobacco smoking (Shopland et al. 1991) . A direct link between exposure to carcinogens contained in tobacco smoke and genetic abnormalities involved in bronchial carcinogenesis is now emerging. Mutations of p53. K-ras and FHIT genes are among the most frequent gene alterations detected to date in lung cancer caused by smoking (Rodenhuis and Slebos. 1988; Takahashi et al. 1989; Sozzi et al. 1996) . The most common mutations found in p53 and K-ras genes are G:C -* T:A transversions, a specific type of mutation induced by benzo(a)pyrene (B(a)P). one of the carcinogens present in tobacco smoke (Suzuki et al. 1992 : Slebos et al. 1991 . Moreover. it has been observed in vitro that B(a)P induces formations of DNA adducts at the major mutational hotspots of p53 (Denissenko et al, 1996) . The FHIT gene. located at chromosome 3pl4.2 and containing the FRA3B fragile site. has recently been found affected by somatic deletions in tumours caused by smoking (Sozzi et al. 1996) .
Tumours that developed in subjects who had never smoked account for less than 10% of all lung cancers and show peculiar (Brownson et al. 1995) . Genetic analyses conducted in small series of lung carcinomas from subjects who had never smoked suggest that their biological behaviour may be different from that of lung cancer caused by smoking. In fact, it has been reported that K-ras mutations in tumours from non-smoking subjects are rare events (Slebos et al. 1991) . and p53 mutations are less frequent than in tumours developed in smoking subjects (Suzuki et al. 1992) . Moreover. p53 mutations in a particular series of nonsmoking lung cancer from atomic-bomb survivors were mostly G:C -e A:T transitions, thus suggesting that endogenous mutational mechanisms could play a more relevant role in neoplasms of non-smoking subjects (Takeshima et al, 1993) . In addition, we have recently observed that the frequency of loss of heterozygosity (LOH) at microsatellite-containing loci located within the FHIT locus was significantly lower in lung adenocarcinomas that developed in subjects who had never smoked compared with that observed in tumours from heavy-smoking subjects (Sozzi et al. 1997) . However, the number of non-smoking lung cancers examined to date, especially for p53 and K-ras mutations, is limited and only one gene has been investigated in each series of tumours.
In the present study we have evaluated the status of p53 and Kras genes. and the presence of LOH at the FHIT locus in a relatively large number of lung adenocarcinomas from subjects who had never smoked. Results were compared with those obtained in 74 A Mareffiet al a corresponding series of lung adenocarcinomas from heavysmoking subjects. In the group of subjects who had never smoked LOH at 3pl4.2 and p53 gene mutations were present in 20% of cases and the two alterations were constantly associated On the other hand, these two abnormalities were not related in the series of adenocarciomas caused by smoing used as control. The type of p53 mutations in tnuours from smoking subjects was different from that observed in non-smoking subjects. No K-ras mutations were observed in non-smoking tmnou, whereas in the group of smoking subjects they were present in 34% of cases. Taken together, the results suggest that lung adenocarcinomas that developed in subjects who had never smoked represent a distinct biological entity involving a coalteration of p53 gene and FHIT locus in one-fifth of cases. (Sozzi et al, 1997) ; 13 additional cases were included in the present study. Thirty-five consecutive cases of lung adenocarcinomas from patients with a history of smoking (>9 years and >10 cigarettes per day), collected during the period 1994-95, were also analysed. All thse lung umours caused by smoking were different from that used in the study by Sozzi et al (1997) . In the group of non-smoking subjects there were 29 (83%) women and six (17%) men with a mean age of 58 years. Thirty-three (94%) of the patients who smoked were men and two (6%) were women with a mean age of 62 years. Information about the exposition to environmental tobacco smoke was carefully collected in all non-smoking patients.
MATERIALS AND
In each case, tumour and normal lung tissue samples were snapfrozen in liquid nitrogen within 10 min of excision and stored at -800C. Immediately adjacent pieces of tumour tissue were fixed and processed for diagnostic histopathology. Histological classification was assessed using light microscopy according to the World Health Organization criteria (World Health Organization, 1982) . All the tumours analysed were lung adenocarcinomas. Patient stage at the time of diagnosis was based on the interational staging system for lung tumours (Mountain 1986 (Blin and Stafford, 1976 p53 gene analysis Genetic analysis of the p53 gene was performed using PCRsingle-strand conformation polymorphism (SSCP) to screen for point mutations in exons 4-9, as described previously (Marchetti et al, 1993) , with the following modifications. After completion of the PCR reaction, the product was diluted 1:5 in loading buffer (95% formamide, 2 mm EDTA, pH 8.3). A 5-Id sample of the diluted samples was denatured (5 min at 90°C), immediately cooled on ice and loaded onto a non-denaturing 6% polyacrylamide gel. Electroporsis was carried out for 14 h at 200C at S W in the presence of 5% glycerol. Upon complete migration the gels were dried and subjected to autoradiography. Direct sequencing of the PCR products was performed with the same primers used for amplification and the sequenase 2.0 Kit (United States Biochemical).
K-ra gene analysis
The mutational analysis of codon 12 of the K-ras gene was performed by oligodeoxynucleotide hybridization, as reported previously (Marchetti et al, 1996) . The primers used to amplify the K-ras gene around codon 12 were: 5'-GGCCTGCTGA-AAATGACTGA-3' and 5'-TGATTCTGAATTAGCTGTAT-3'. The PCR reaction was programmed as follows: initial denaturation, 4 min at 94°C; amplification, 30 s at 940C, 30 s at 540C, 1 min at 720C for 35 cycles; elongation, 10 min at 720C. The amphfied products of the PCR reaction were denatured and blotted onto nylon membranes, which were then hybridized separately with 32P-labelled mutation-specific oligonucleotide probes.
Statstical analysis
The different variables of the analysed tmours were tested for association using the chi-square and Fisher's exact tests using the Brish Journal of Cancer (1998) 78(1), [73] [74] [75] [76] [77] [78] Genetic analys of non-smokers' lung tumours 75 
p53
A SSCP assay was performed on tumour-derived genomic DNA and corresponding normal lung tissues to cover exons 4-9 of p53. PCR was repeated at least twice for each sample and only the reproducible cases were taken. Bands of mobility shift were sequenced to identify the mutations and exclude known polymorphisms. Seven (20%) of adenocarcinomas from never-smoking subjects and eight (23%) of adenocarcinomas caused by smoking showed p53 mutations. In non-smoking tumiours three of the seven genomic alterations of the p53 gene were G:C-4A:T transitions, three were deletions and one was a G:C-*T:A transversion (Table  1 ). In the group of smoking subjects five of the eight mutations were G:C-*T:A transversions, two were A:T-*G:C transitions and one was a single-base insertion (Table 2) . (1998) 78(1), [73] [74] [75] [76] [77] [78] Tumours from non-smokl9 subjects (Boldog et al, 1997) . On the other hand. p53 mutations appear uncommon in RER+ colorectal carcinomas and gastric tmours (Wu et al, 1994 : Renault et al. 1996 . In the light of these observations, our results suggest that in tumours from non-smoking subjects LOH at the FHIT locus are not a consequence of mismatch repair deficiency, but may be related with the genomic instability that accompanies p53 mutations. However, a concomitant association of 3pl4.2 deletions and p53 gene abnormalities was not frequent in tumours from heavy smoking subjects, indicating that this association is not a constant event in human cancer. In particular, in tunours from smoking subjects, FHIT gene alterations may be pimarily related to carinogens present im tobacco smoke and not a consequence of p53 inactivation. In the series of smoking patients p53 mutations were significantly associated with metastatic involvement of hilar/mediastinal lymph nodes and advanced stages of disease, in agreement with previous results (Marchetti et al, 1993; Lee et al, 1994) . In nonsmoking subjects a trend towards these associations was observed. but the data did not reach statistically significant values.
In conclusion, our results indicate that lung tumours developed in never-smoking subjects represent a distinct biological entity in which LOH at the FHIT locus and p53 mutations are concomitantly present in 20% of cases. On the contrary, this association of molecular events was uncommon in tumours from heavy-smoking subjects. As different p53 mutations were observed in these two groups of lung tumours. we are tempted to hypothesize that LOH at the FHIT locus in never-smoking subjects' lung cancer may be dependent from the particular type of p53 mutations (G:C-*A:T transitions and deletions). At this point it should be interesting to evaluate the status of FHIT and p53 in other forms of human malignancies in order to assess whether the association of genetic abnormalities observed is restricted to lung cancer in non-smoking subjects or common to other forms of human neoplasms.
